Harmony Biosciences Holdings, Inc. HRMY
37.02 USD -0.89 (-2.35%)
At closeNov 4, 2026, 7:01 AM EST
39.38 +2.36 +6.37%
Pre-market · Nov 4, 7:01 AM ET
36.38 Day range 38.74
25.90 52-week range 43.49
- YTD
- -1.07%
- 1 year
- +20.51%
News
zacks.com Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target Needham analyst Ami Fadia reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $50 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $55 price target.- benzinga.com Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target Needham analyst Ami Fadia reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $50 price target.
benzinga.com This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Consider ACMR stock: analysts' thoughts
benzinga.com Wolfe Research Initiates Coverage On Harmony Biosciences Hldgs with Outperform Rating, Announces Price Target of $60 Wolfe Research analyst Rudy Li initiates coverage on Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform rating and announces Price Target of $60.
benzinga.com Truist Securities Maintains Hold on Harmony Biosciences Hldgs, Raises Price Target to $34 Truist Securities analyst Danielle Brill maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Hold and raises the price target from $29 to $34.
benzinga.com Harmony Biosciences Says New Data Supports Neurology Pipeline Harmony Biosciences stock jumped after record Q2 revenue, an earnings beat, strong WAKIX sales and updated analyst price targets.
benzinga.com Needham Maintains Buy on Harmony Biosciences Hldgs, Raises Price Target to $50 Needham analyst Ami Fadia maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and raises the price target from $45 to $50.- benzinga.com Harmony Biosciences Q2 EPS $1.28 Beats $0.94 Estimate, Sales $261.300M Beat $248.406M Estimate Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $1.28 per share which beat the analyst consensus estimate of $0.94 by 36.17 percent. This is a 39.13 percent increase over earnings of…
benzinga.com Harmony Biosciences Hldgs Affirms FY2026 Sales Guidance of $1.000B-$1.040B vs $1.020B Est Harmony Biosciences Hldgs (NASDAQ:HRMY) affirms FY2026 sales outlook from $1.000 billion-$1.040 billion to $1.000 billion-$1.040 billion vs $1.020 billion estimate.
benzinga.com Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $51 Mizuho analyst Graig Suvannavejh maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform and raises the price target from $50 to $51.- benzinga.com HC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $55 price target.
- benzinga.com Harmony Biosciences Reports Preliminary Q2 WAKIX Sales Of ~$261M, Up 30% YoY; Appoints Stephen Mollichella As Interim CFO Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced preliminary, unaudited second quarter 2026 net product revenue for WAKIX® (pitolisant) of approximately $261 million, representing a…
benzinga.com Harmony Biosciences Hldgs Affirms Prelim FY2026 Sales Guidance of $1.000B-$1.040B vs $1.014B Est Harmony Biosciences Hldgs (NASDAQ:HRMY) affirms prelim FY2026 sales outlook from $1.000 billion-$1.040 billion to $1.000 billion-$1.040 billion vs $1.014 billion estimate.
benzinga.com Deutsche Bank Maintains Hold on Harmony Biosciences Hldgs, Raises Price Target to $36 Deutsche Bank analyst David Hoang maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Hold and raises the price target from $30 to $36.- benzinga.com Truist Securities Maintains Hold on Harmony Biosciences Hldgs, Raises Price Target to $29 Truist Securities analyst Danielle Brill maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Hold and raises the price target from $25 to $29.
- benzinga.com Harmony Biosciences Hldgs Affirms FY2026 Sales Guidance of $1.000B-$1.040B vs $1.020B Est Harmony Biosciences Hldgs (NASDAQ:HRMY) affirms FY2026 sales outlook from $1.000 billion-$1.040 billion to $1.000 billion-$1.040 billion vs $1.020 billion estimate.
- benzinga.com Harmony Biosciences Q1 Adj. EPS $0.55 Misses $0.69 Estimate, Sales $215.400M Miss $225.227M Estimate Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $0.55 per share which missed the analyst consensus estimate of $0.69 by 20.29 percent. This is a 46.6 percent decrease over earnings…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Harmony Biosciences Appoints Glenn Reicin CFO, Effective Immediately; Co. Reiterates 2026 Net Product Revenue Outlook Range $1B - $1.04B Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting Harmony's continued focus on strategic…
- benzinga.com Harmony Biosciences Announces The Appointment Of Peter Anastasiou As Chief Operating Officer Appointments support Harmony's next phase of growth and long‑term value creationHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Peter Anastasiou as Chief Operating…
- benzinga.com UBS Maintains Neutral on Harmony Biosciences Hldgs, Lowers Price Target to $36 UBS analyst So Youn Shim maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Neutral and lowers the price target from $46 to $36.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $55 price target.
benzinga.com CAVA Group To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Wednesday - benzinga.com B of A Securities Maintains Underperform on Harmony Biosciences Hldgs, Lowers Price Target to $28 B of A Securities analyst Jason Gerberry maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Underperform and lowers the price target from $32 to $28.
- benzinga.com Needham Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $44 Needham analyst Ami Fadia maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and lowers the price target from $46 to $44.
benzinga.com Harmony Biosciences Hldgs Earnings Review: Q4 Summary - benzinga.com Harmony Biosciences Q4 Adj. EPS $0.57 Misses $0.90 Estimate, Sales $243.776M Beat $240.286M Estimate Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $0.57 per share which missed the analyst consensus estimate of $0.90 by 36.74 percent. This is a 48.18 percent decrease over earnings…
benzinga.com Earnings Scheduled For February 24, 2026 
benzinga.com A Peek at Harmony Biosciences's Future Earnings - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com The FDA Approves Harmony Biosciences' Supplemental Application For Wakix (Pitolisant) Tablets For Cataplexy In Pediatric Patients 6 Years Of Age And Older With Narcolepsy WAKIX was approved by the FDA in August 2019 for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy, with approval expanded to include cataplexy in adult patients…
benzinga.com Where Harmony Biosciences Hldgs Stands With Analysts - benzinga.com Harmony Biosciences Hldgs Raises FY2025 Sales Guidance from $845.000M-$865.000M to $868.000M vs $862.659M Est Harmony Biosciences Hldgs (NASDAQ:HRMY) raises FY2025 sales outlook from $845.000 million-$865.000 million to $868.000 million vs $862.659 million estimate.
- benzinga.com Harmony Biosciences Reports Preliminary 2025 WAKIX Net Revenue of ~$868M, $243M In Q4; Sees 2026 Revenue Of $1B-$1.04B WAKIX 2025 Preliminary Net Revenue of ~$868 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in NarcolepsyOn Track to Extend the Pitolisant Franchise…
benzinga.com 6 Analysts Have This To Say About Harmony Biosciences Hldgs - benzinga.com Truist Securities Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $45 Truist Securities analyst Danielle Brill maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and lowers the price target from $48 to $45.
- benzinga.com Beacon Biosignals Collaborates With Harmony Biosciences To Incorporate Quantitative EEG Measurements Into Two Of Harmony's Phase 3 Studies Of HBS-301 For Narcolepsy And Idiopathic Hypersomnia Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (NASDAQ:HRMY), a pharmaceutical company dedicated to…
- benzinga.com Harmony Biosciences' EPX-100 Shows ~50% Seizure Reduction And Favorable Safety In Dravet Syndrome Phase 3 Extension Data Presented At AES 2025 Data presented at the 2025 American Epilepsy Society Annual MeetingHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced the presentation of initial open-label extension (OLE) data from…
- benzinga.com Harmony Biosciences To Highlight New Open-Label Extension Data From Its Investigation Of EPX-100 In Ongoing Phase 3 ARGUS Trial For Treatment Of Dravet Syndrome At 2025 AES Annual Meeting Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that it will highlight new open-label extension data from the company's investigation of EPX-100 (clemizole hydrochloride) in the…
- benzinga.com Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $46 Mizuho analyst Graig Suvannavejh maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform and raises the price target from $39 to $46.
benzinga.com Earnings Scheduled For November 4, 2025 
benzinga.com Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Earnings Scheduled For August 5, 2025
benzinga.com Earnings Scheduled For May 6, 2025 - benzinga.com Earnings Scheduled For February 25, 2025
- benzinga.com Earnings Scheduled For February 22, 2024 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.